Artelo Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2014
Net Income	-9.29	-10.08	-7.44	-4.66	-2.17	Upgrade
Depreciation & Amortization	0.04	0.04	0.01	0	0	Upgrade
Share-Based Compensation	1.02	2.46	1.53	0.38	0.43	Upgrade
Other Operating Activities	0.02	-0.42	-0.24	-0.07	-1.05	Upgrade
Operating Cash Flow	-8.21	-8.01	-6.14	-4.35	-2.79	Upgrade
Capital Expenditures	0	0	0	0	-0	Upgrade
Change in Investments	3.51	2.96	-3.44	0	0	Upgrade
Other Investing Activities	-	-	-	-	-1.5	Upgrade
Investing Cash Flow	3.51	2.96	-3.44	0	-1.5	Upgrade
Share Issuance / Repurchase	0.57	0	14.12	1.98	8.38	Upgrade
Debt Issued / Paid	0	0	-0.01	0	0	Upgrade
Financing Cash Flow	0.57	0	14.11	1.98	8.38	Upgrade
Exchange Rate Effect	0.06	-0.22	-0.05	0.08	0	Upgrade
Net Cash Flow	-4.07	-5.27	4.49	-2.28	4.09	Upgrade
Free Cash Flow	-8.21	-8.01	-6.14	-4.35	-2.79	Upgrade
Free Cash Flow Per Share	-2.77	-2.83	-4.93	-17.59	-19.29	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).